Rebecca Elstrom
Fate Therapeutics (United States)(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Akt Stimulates Aerobic Glycolysis in Cancer Cells(2004)1,453 cited
- → The CD28 Signaling Pathway Regulates Glucose Metabolism(2002)1,417 cited
- → Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma(2015)1,102 cited
- → Utility of FDG-PET scanning in lymphoma by WHO classification(2003)435 cited
- → Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL(2019)361 cited
- → The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation(2005)352 cited
- → Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma(2009)336 cited
- → Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma(2010)318 cited
- → Treatment of PTLD with Rituximab or Chemotherapy(2006)257 cited
- → Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma(2013)212 cited